March 2012. Volume 8. Number 1

Results of antenatal steroids in the limit of viability

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA. 2011;306:2348-58.
Reviewers: González de Dios J1, Molina Arias M2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 29/01/2012
Acceptance date: 30/01/2012
Publication date: 01/02/2012

Abstract

Authors' conclusions: among infants born at 23 to 25 weeks´ gestation, antenatal exposure to corticosteroids compared with nonexposure was associated with a lower rate of death or neurodevelopmental impairment at 18 to 22 months.

Reviewers' commentary: lacking evidence from difficult to perform controlled benefit-risk-cost trials, current data could allow the use of a single course of therapy with antenatal corticosteroid for mothers of premature infants at 23 to 25 weeks’ gestation. This decision should take into consideration the availability of the rest of treatments who are needed by these infants around the limits of viability, as well as the ethical issues prevailing in clinical practice.

How to cite this article

González de Dios J, Molina Arias M. Resultados de los corticoides prenatales en el límite de la viabilidad. Evid Pediatr. 2012;8:12.

AVC | Critically appraised articles

Carlo WA, McDonald SA, Fanaroff AA, Vohr BR, Stoll BJ, Ehrenkranz RA et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA. 2011;306:2348-58.
Reviewers: González de Dios J1, Molina Arias M2.
1Departamento de Pediatría. Hospital General Universitario de Alicante. España.
2Servicio de Gastroenterología y Nutrición. Hospital Infantil Universitario La Paz. Madrid. España.
Correspondence: Javier González de Dios. Email: javier.gonzalezdedios@gmail.com
Reception date: 29/01/2012
Acceptance date: 30/01/2012
Publication date: 01/02/2012

Structured Abstract



How to cite this article

González de Dios J, Molina Arias M. Resultados de los corticoides prenatales en el límite de la viabilidad. Evid Pediatr. 2012;8:12.

References

  1. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2006;3:CD004454
  2. González de Dios J, Balaguer Santamaría A. No se recomienda la utilización de ciclos múltiples de corticoides prenatales en el riesgo de parto prematuro. Evid Pediatr. 2009;5:8.
  3. Onland W, de Laat MW, Mol BW, Offringa M. Effects of antenatal corticosteroids given prior to 26 weeks' gestation: a systematic review of randomized controlled trials. Am J Perinatol. 2011;28:33-44.
  4. Mori R, Kusuda S, Fujimura M; Neonatal Research Network Japan. Antenatal corticosteroids promote survival of extremely preterm infants born at 22 to 23 weeks of gestation. J Pediatr. 2011;159:110-114.e1.
  5. Hayes EJ, Paul DA, Stahl GE, Seibel-Seamon J, Dysart K, Leiby BE et al. Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation. Obstet Gynecol. 2008;111:921-6.
  6. Abbasi S, Oxford C, Gerdes J, Sehdev H, Ludmir J. Antenatal corticosteroids prior to 24 weeks' gestation and neonatal outcome of extremely low birth weight infants. Am J Perinatol. 2010;27:61-6.
01/02/2012

Linked Comment